Mahesh Kandula, Managing Director & CEO
Drug Design and Development, Innovation & IP
Mahesh brings over >16 years of scientific and entrepreneurial experience in the life science industry. Mr. Kandula has been named an inventor on 72 United States Issued Patents, 29 United States Patent Pending Applications and more than 181 International Patent Applications. Mr. Kandula received his Master of Technology degree from IIT Kharagpur.
CDO & COO
Subbu Apparsundaram is an established scientist with extensive experience in drug discovery and development. Dr. Subbu founded VClinBio that entered into strategic partnership with Cellix Bio. Previously, Subbu was a Drug Discovery Scientist at Hoffmann-La Roche Pharmaceuticals, and a faculty at the University of Kentucky Medical Center. He has published several peer reviewed research papers.
Richard Minicus is a finance and business development professional with extensive M&A and venture capital investment experience focused on early-stage and established biomedical and life science companies. Rich worked at Becton Dickinson for 16 years in corporate development and venture capital investing and at Pfizer for five years in business development. Rich holds an MBA from Harvard Business School, and Master of Science in Biology from Fairleigh Dickinson University.
Paul Jeffrey is an accomplished Pharmaceutical business consultant and leader with demonstrated new product development and business development capabilities. He has over 30 years of industry experience building product value by leading global teams and creating and implementing clinical and marketing programs to maximize commercial positioning and launch success. He has led commercial development team and alliance partnerships while at Pfizer as VP of Global Commercial Development group.
Bruce has worked across a wide range of pharmaceutical commercialization strategy, analysis, and implementation over the past 28 years at Pfizer and McKinsey. At Pfizer, he led the Management Science Group and the Resource Allocation Group where besides supporting sales and marketing optimization, he worked with business development and commercial development. He played key roles on various co-promotion deals including Lipitor, Celebrex, Spiriva, and Eliquis, especially negotiating promotion resource levels. Prior to pharmaceuticals, Bruce gained significant corporate finance experience with Morgan Stanley, Stern Stewart, and McKinsey. Bruce holds an MBA from the University of Chicago, and Bachelor of Science in Civil Engineering from the Massachusetts Institute of Technology.
Dr. Douglas Greene
Medical Affairs & Strategic Advisor
Douglas Greene, MD, served as Executive Vice President, Chief Scientific Officer and Head, Research and Development, Ikaria Pharmaceuticals; Senior Vice President and Senior Scientific Advisor and Head of Corporate Regulatory Development at Sanofi-Aventis; Executive Vice President of Clinical Sciences and Product Development at Merck Research Laboratories and Corporate Officer of Merck, Inc.; served as member of the US Food and Drug Administration’s Endocrinologic and Metabolic Drug Advisory Committee and acted as Chairman of the Advisory Committee.
Dr. Greene was Professor of Internal Medicine, Director of the Michigan Diabetes Research and Training Center, and Chief, Division of Endocrinology & Metabolism at the University of Michigan School of Medicine. Dr. Greene was Associate Professor of Internal Medicine, Director of the Diabetes Research Laboratory and Head of the General Clinical Research Center at the University of Pittsburgh, and Assistant Professor of Internal Medicine at the University of Pennsylvania. Dr. Greene completed a post-doctoral research fellowship at the Cox Research Institute at the University of Pennsylvania, and Internal Medicine internship and residency at Johns Hopkins Hospital. Dr Greene holds an MD from the Johns Hopkins School of Medicine.
Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. Previously, Bob held senior level executive roles in Wyeth and Johnson & Johnson. Most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc.
CMC & Regulatory
Dr. Prabha Bhandari has more than 3 decades of professional leadership in Pharmaceutical Industry with expertise in Global API Regulatory Affairs including New Chemical Entities. She has rich experience in Corporate Quality Assurance at API Operations, Supervision of Global Regulatory Agencies’ audits (Viz. FDA US; EMA, Europe; TGA Australia; COFEPRIS Mexico; ANVISA Brazil; PMDA Japan etc), Data Reliability & Remediation and API Process Development in compliance with Global Regulatory requirements. She is Ph.D in Chemistry from Central Drug Research Institute, Lucknow, India and did Post-doctoral Research at Trinity College, Dublin, Ireland; University of Strathclyde, Glasgow, Scotland and University of Nottingham, England.
CMC & Regulatory
Dr. Frank Diana is experienced in the areas of CMC, Pharmaceutical and Analytical Development. Dr. Diana had a 40-year career in the Pharmaceutical Industry working for Endo Pharmaceuticals, Johnson & Johnson and DuPont Pharmaceuticals mostly in Pharmaceutical Development, Technical Operations and Quality. He obtained his PhD from St. John’s University in NY and is an adjunct professor in the RA/QA graduate program at Temple University’s School of Pharmacy teaching several courses including Global CMC Issues.
Ashok Rampal has more than 3 decades of experience in R & D management, drug delivery and formulation development in renowned companies like Knoll Pharmaceuticals, Ranbaxy-Lilly, Ranbaxy Research Labs and Alkem Labs Ltd. Mr. Rampal holds Master’s degree in Pharmaceutics from Panjab University and Diploma in Business Management from Mumbai. He is inventor in more than 110 patent applications.
K B Sunil Kumar
Specialized in pharmaceutical toxicology and preclinical development with more than 25 years of professional experience in Drug Discovery and Development. Record of accomplishment of leading the planning, execution and authoring multiple successful Investigational New drug applications [INDs] in different therapeutic areas with global regulatory authorities. Dr. Sunil Kumar holds a Ph.D from University of Kerala, Thiruvananthapuram, Kerala, India.
Dr. Mudher Albassam has extensive experience in nonclinical development, pathology, nonclinical safety/risk assessment and toxicology. He was a Principal Director and Senior Director in Toxicology & Pathology at Roche Pharmaceuticals. He obtained his PhD on Veterinary Pathology from Purdue University and MS in Veterinary Pathology from the University of Guelph.
Sivanesan has > 12 years of experience in nonclinical development of various pharmaceutical products. Experienced in planning and conducting nonclinical studies for new chemical entities and evaluating the safety profile of a drug candidate in various therapeutic areas. He received bachelor degree in Veterinary Science and Master Degree in Veterinary pathology. He is also a certified Diplomate of American Board of Toxicology [DABT].